Inve India ▾

Infinium Pharma share price & results

Infinium Pharma· Healthcare

Results to
Mar 2026
Ownership as of
Sept 2026

Gujarat-based iodine-chemistry specialist making iodine derivatives, APIs and intermediates for pharma, agro and specialty-chemical customers, now expanding into contrast-media intermediates.

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue84.0 ₹ crore+27.3% YoYQuarterly, as filedQuarter to Mar 2026Revenue from operations as filed.
Operating margin10.0 %−3.0 pts YoYOperating profit / revenueQuarter to Mar 2026For the quarter; a change is in percentage points.
Net profit5.0 ₹ crore0.0% YoYQuarterly, as filedQuarter to Mar 2026Profit after tax as filed.
Return on equityUnavailable−1.7 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin12.79 %+36.9 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable+7.1 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Mar 2026

Price

₹286 +0.51% · +₹1.45

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +13.5% 1Y

₹200₹250₹300Oct 25Dec 25Jan 26Mar 26Apr 26Jun 26Jul 26Sept 26Oct 26

1Y: ₹252.05 on 24 Oct 2025 → ₹286. High ₹317 (12 Oct 2026), low ₹191.05 (12 Jun 2026).

Previous close
₹284.55
Market cap
₹462 Cr
52-week range
₹191.05 – ₹317
One year
+13.49%
Price to earnings (FY ending Mar 2026)
38.66×
Return on equity (FY ending Mar 2026)
10.35%

Overview

Symbol
NSE:INFINIUM
Exchange
NSE
Currency
INR

What Infinium Pharma does

Based on the company's own presentations, annual report and earnings calls.

Infinium PharmaChem manufactures iodine-based derivatives, intermediates and APIs at its GIDC Sojitra (Anand, Gujarat) plant, supplying pharmaceutical, agrochemical, nutraceutical and specialty-chemical customers under a CRAMS (custom research and manufacturing) model across 30+ export countries. It secures its key raw material through a US joint venture (IBL Elements Inc., Texas) that extracts iodine from oilfield brine under a 30-year supply agreement, and is building a new facility to forward-integrate into contrast-media intermediates such as Atipa dichloride for medical-imaging use. Group entities extend the business into API trading (Infinium Healthcare Pvt Ltd), bio-coal/biomass fuel (Infinium Green Energy Pvt Ltd) and cross-border chemical trading with China (Shanghai Tajilin JV).

Segments

  • Iodine derivatives & APIs
  • Contrast media (under development)
  • API trading
  • Bio-coal / green energy
  • China trading JV
Installed manufacturing capacity
1,800 MTPA (iodine derivatives, GIDC Sojitra plant, Gujarat)
Annual production volume
293 MT
Product portfolio
220+ iodine derivatives
APIs manufactured
19
Export footprint
30+ countries
Captive iodine supply
~120 MT/year via 30-year JV with IBL Elements Inc. (US brine extraction)
Founded 2003Headquarters Vallabh Vidyanagar, Gujarat, India Company website

Your own record

Start an Inve Case for Infinium Pharma

Free account: one company. Everything above stays public.

Write why you follow Infinium Pharma and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse Infinium Pharma

Guides on how to read this kind of business and the numbers that matter.